These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 10917400)

  • 1. Therapeutic spectrum of nemonapride and its relationship with plasma concentrations of the drug and prolactin.
    Kondo T; Mihara K; Yasui N; Nagashima U; Ono S; Kaneko S; Ohkubo T; Osanai T; Sugawara K; Otani K
    J Clin Psychopharmacol; 2000 Aug; 20(4):404-9. PubMed ID: 10917400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between side effects of nemonapride and plasma concentrations of the drug and prolactin.
    Kondo T; Ishida M; Tokinaga N; Mihara K; Yasui-Furukori N; Ono S; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb; 26(2):287-91. PubMed ID: 11817505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms.
    Yasui-Furukori N; Kondo T; Ishida M; Furukori H; Suzuki A; Kaneko S; Inoue M; Otani K
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):53-7. PubMed ID: 11853119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients.
    Suzuki A; Mihara K; Kondo T; Tanaka O; Nagashima U; Otani K; Kaneko S
    Pharmacogenetics; 2000 Jun; 10(4):335-41. PubMed ID: 10862524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.
    Takahashi H; Kamata M; Yoshida K; Ishigooka J; Higuchi H
    J Clin Psychiatry; 2006 Oct; 67(10):1577-82. PubMed ID: 17107250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remoxipride in schizophrenia: effects on plasma prolactin.
    Chouinard G; Turnier L; Kallai-Sanfacon MA
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):599-603. PubMed ID: 2868493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia.
    Müller MJ; Wetzel H; Eich FX; Rein W; Puech A; Benkert O;
    J Clin Psychopharmacol; 2002 Dec; 22(6):554-60. PubMed ID: 12454554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients.
    Yasui-Furukori N; Saito M; Nakagami T; Furukori H; Suzuki A; Kondo T; Kaneko S
    J Psychopharmacol; 2010 Jul; 24(7):987-94. PubMed ID: 19477882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and risk factors of acute dystonia in schizophrenic patients treated with nemonapride, a selective dopamine antagonist.
    Kondo T; Otani K; Tokinaga N; Ishida M; Yasui N; Kaneko S
    J Clin Psychopharmacol; 1999 Feb; 19(1):45-50. PubMed ID: 9934942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
    Goff DC; Posever T; Herz L; Simmons J; Kletti N; Lapierre K; Wilner KD; Law CG; Ko GN
    J Clin Psychopharmacol; 1998 Aug; 18(4):296-304. PubMed ID: 9690695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse effects of zotepine and their relationship to serum concentrations of the drug and prolactin.
    Kondo T; Otani K; Ishida M; Tanaka O; Kaneko S; Fukushima Y
    Ther Drug Monit; 1994 Apr; 16(2):120-4. PubMed ID: 7912012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics.
    Spina E; Avenoso A; Facciolà G; Scordo MG; Ancione M; Madia AG; Ventimiglia A; Perucca E
    Psychopharmacology (Berl); 2000 Jan; 148(1):83-9. PubMed ID: 10663421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of prolactin elevation with antipsychotic medications on subjective quality of life in patients with schizophrenia.
    Kaneda Y
    Clin Neuropharmacol; 2003; 26(4):182-4. PubMed ID: 12897637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catechol-O-methyltransferase gene variants may associate with negative symptom response and plasma concentrations of prolactin in schizophrenia after amisulpride treatment.
    Chen CY; Yeh YW; Kuo SC; Ho PS; Liang CS; Yen CH; Lu RB; Huang SY
    Psychoneuroendocrinology; 2016 Mar; 65():67-75. PubMed ID: 26724569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-performance liquid chromatographic determination of nemonapride and desmethylnemonapride in human plasma using an electrochemical detection.
    Nagasaki T; Ohkubo T; Sugawar K; Yasui N; Ohtani K; Kaneko S
    J Chromatogr B Biomed Sci Appl; 1998 Sep; 714(2):293-8. PubMed ID: 9766869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene.
    Mihara K; Kondo T; Suzuki A; Yasui N; Nagashima U; Ono S; Otani K; Kaneko S
    Psychopharmacology (Berl); 2000 Apr; 149(3):246-50. PubMed ID: 10823405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nemonapride for the treatment of schizophrenia.
    Satoh K; Someya T; Shibasaki M
    Am J Psychiatry; 1997 Feb; 154(2):292. PubMed ID: 9016292
    [No Abstract]   [Full Text] [Related]  

  • 18. Remoxipride in schizophrenia. A preliminary report.
    den Boer JA; Verhoeven WM; Westenberg HG
    Acta Psychiatr Scand; 1986 Oct; 74(4):409-14. PubMed ID: 2880457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
    Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
    Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity.
    Chouinard G
    J Clin Psychopharmacol; 1987 Jun; 7(3):159-64. PubMed ID: 2885345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.